Skip to main content

Pfizer Inc Investor Event Transcript, Nov 17, 2026

Pfizer Inc (PFE)

Pfizer CEO Albert Bourla said launch products are growing 32% this quarter and already amount to roughly $15-16 billion annualized revenue. He also said Pfizer beat analyst EPS expectations 11 times out of 11 over the last 11 quarters, and that the company expects high single-digit growth over the next five years. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - PFE 2026-11-17

Akash Tiwari, Analyst — Jefferies

You That's better. All right. Good morning, everyone. Day two of our Jeffries London Healthcare Conference. Been really great to see everyone in the attendance. My name is Akash Tiwari. For those who don't know me, I head our biotech and research efforts internally within the firm. I have the pleasure of hosting Albert, CEO of Pfizer, one of the more impactful leaders when it comes to understanding what's going on with U.S. healthcare, and that's going to be something we'll talk about. Albert, why don't I hand it off to you for some intro remarks, and we'll get started.

Albert Bourla, CEO

Thank you. It's a great pleasure to be here. Pfizer had entered the LOE period, which was highly anticipated, and it's expected to last another two years. This is a period for which we were preparing for a long time. After the COVID success, we invested more than anyone else. Actually, we invested $80 billion in acquisitions that will help us overcome through new launches and through building pipeline, because many of the acquisitions were platforms. To be able to overcome the headwinds of the LOE period. Actually, 80 billions, to give you magnitude, is the largest, and the second one is around 40. in the post COVID period. So it's a significant, uh, more than anybody else. In addition to that, we control our costs and we build our pipeline. So I think the first data. We are showing that the strategy works well. Our launch products, they are growing at 32% this quarter, and it's accelerating, actually, the growth rather than decelerating. They are already amounting to a rounding of $15-16 billion annualized revenues and going. The pipeline, it is progressing very nice. Twenty phase three studies started this year alone, almost double than a year before, right? So it's a significant also acceleration of building the pipeline. And we, in the last 11 quarters, we were able to beat analyst expectations 11 times out of 11 in EPS and 10 times out of 11 in revenue. So it's high quality. So it's a company that knows what wants to achieve. We have a plan and we are executing it very well. So I'm very optimistic that we will enter, we will exit the LOE period. As we said, with a high single-digit growth in the next five years.

Akash Tiwari, Analyst — Jefferies

Right. And maybe to that point, and you've talked about 2028 being the end of kind of that LOE period, and then the high single-digit growth going from there. When you look at street estimates, because I feel like, to your point, you've been telling everyone, let's not focus on the next couple of years. Let's think about the kind of 2030-plus story on Pfizer. Where has your team gotten more confident on, on the pipeline side, over the last couple of years? What do you think we're missing about the 2030-plus story on Pfizer that you have a ton of confidence on right now?

Albert Bourla, CEO

I will say that our revenue streams is for... The LOE products. I think there is no big discrepancy because it's easy to predict. There is analogs that knows how the products will perform. Then there is all the inline portfolio, the products that they have long history of selling. And over there also, there is not much discrepancy with the street because you can predict them quite well. Where there is discrepancy in the street are in two categories. Pipeline, you mentioned, it's only one of them. One is the new launches that are coming now. In all of these products, I can go one after the other. El Rexfield, it's a new launch. Huge disconnect between us and the street. The street has us at 600 million and has the competing product at 5 billion. And there is something wrong with that. What are the assumptions? Because we are aspiring to have a profile with the same efficacy and maybe better tolerability. So I would challenge that. Nurtec, the street has us at $2.5 billion with another new launch product. We are already at two. So it's going. And I can go on and on in new launches that are very significant behind what they should be. And then on the pipeline, again, the obesity portfolio, very big disconnect. The CDK4, very big disconnect. The PD-1, VGF, very big disconnect. So over there, I think the disconnect is either because some of you, they don't even model them, and some of you that are very conservative. As pipeline will start having redoubts, I think we will be able to close the gap and come to the real number.

Akash Tiwari, Analyst — Jefferies

Understood. And I definitely want to talk about the pipeline, but I also want to hit on, you know, to your team's credit, you guys have had $7.2 billion in net savings so far. You've got an OPEX of around $25 billion. And there is this, but... When I talk to you, and especially when you talk about AI and efficiencies, and I remember you were in our conference in June, and you said, my single biggest priority is implementing AI, and really in every part of our organization. Should we really think about this 7.2 billion as, okay, well, this is what Pfizer's done, and this is the cost cut, and we're done? I look at the way you think about efficiency gains with AI and then also just efficiency gains within the company as this kind of like ongoing process. And you might actually have even more operating leverage than people realize. Talk to me about operating efficiencies, whether it's through AI or else, as we go out into the end of the decade, where you feel like maybe we're not understanding what's going on on the ground level.

Albert Bourla, CEO

The 7.2 billion is real. It's going to be materialized by this year, which is ending in a month or so. So it's a testament to us that we were able to do it over a few years without affecting the top line. Actually, the top line is doing much better than anybody else would expect. We already announced an additional one and a half billion dollars. And you're right that with AI, I don't think that there is limitation as to what... I will tell you how I see the world. I see the world, but right now... We are having China growing their biotech business and having ambition to become global players. I think they will be successful. I think by year 2030, they will represent my major competition. It's not going to be AstraZeneca or Lilly. It's going to be, I think, Chinese companies. They come and they introduce a different league. As Lily, AstraZeneca, one is better in sales, one in marketing, one in R&D, but we are pretty much one category. They are coming half the cost, three, four times the speed. If we want to compete with them by year 2030, we need to be half the cost, three, four times the speed. That sounds very difficult to achieve. Unless if AI delivers on the promise. And AI for me is the biggest lever to be able to build the Pfizer of the future. But I repeat needs to be productive at three, four times the speed and half the cost.

Akash Tiwari, Analyst — Jefferies

Understood. You know, it was interesting, and look, it's always a sad announcement when people get laid off, there's no doubt. But I saw with AstraZeneca, I think they recently laid off, I think it was 600 people, it was 120 million in costs. I do think that kind of stuck out to us when we think about SG&A and really how costly it can end up being. So we've talked about speed, and that'll be a process, but when we think about where AI could have the biggest efficiency gain... I noticed that every pharma basically beat on SG&A in Q3, and we're not looking at the transformation that maybe is happening right now. So when you think about AI allowing your sales force to target the right patient more productively, do more with less, do you feel like that's actually where the first impact on the P&L will be with AI, is sales force efficiency adoptions?

Albert Bourla, CEO

I know. I think the first impact of AI probably will be in enabling functions, which are more supporting. And then what will follow will be But sales will be the last one, probably marketing. So every single aspect of our cost base will be affected and will become more productive. Now, the question is what you want to do with it. You want to do more with the same? You want to do more with less? Or you want to do less with less? And we want to do more with less.

Akash Tiwari, Analyst — Jefferies

Understood. Now, obviously, it's been a blue wave, as they say. There's been a shifting political environment, I think, with the U.S., and it's interesting. When I talk to a lot of the companies, one of the things that actually comes up consistently is the MFN dynamic and this issue of, hey, the U.S. is, you know, Driving so much of innovation and spending so much on health care that there needs to be a more equitable shift to other developed nations. That's not a Trump incentive dynamic. That is going to be a long-term dynamic that we're going to see for the next decade plus. Do you agree with that, that despite the fact that we're seeing maybe Democrats get elected, we are going to see maybe MFN pricing and the dynamics associated with that linger?

Albert Bourla, CEO

Yeah, I agree with that. I think that it is a situation that is not sustainable. The public is aware that American patients are paying higher for their medicines than German patients, French patients, British patients, and they don't accept that. It's okay to understand if patients in low-income countries are having different prices, but not in these ones. So something needs to be done about it, and MFN was the way to get off a lot of steam from a pot that was ready to explode. But make no mistakes. I think the direction is the same for Democrats or Republicans. You can say they don't want that to be resolved. They cannot explain to their constituents why this is happening. So that needs to change.

Akash Tiwari, Analyst — Jefferies

So, if this is a long-term concern, Do you think when, you know, the street is thinking about where revenue is generated for a global pharmaceutical firm like yours, I think historically we thought, okay, you know, 60, 40 for some of your large products. I'm hearing, you know, the Middle East, South America, Korea. I mean, there are markets, India, that are suddenly becoming more and more important when we think about revenue streams for pharma companies. And there's just this kind of increasing realization that Europe will now be materially less important. Just in terms of revenues, is that something you would agree with? What are some emerging market opportunities, especially with, let's say, your obesity portfolio, you think the street's really not appreciating right now?

Albert Bourla, CEO

Until now, that's true that Europe was becoming actually less important, meaning that the percentage of sales that we were realizing from Europe was shrinking rather than growing. It is true that other markets are... Becoming way more important to us than before. You mentioned a lot of that in emerging markets, what we call, but Latin America, Brazil, Mexico is getting significant traction. Asian markets are getting significant traction, and Middle East is getting significant traction. But Europe will always remain a very important market for medical innovation.

Akash Tiwari, Analyst — Jefferies

Now, let's talk a bit about obesity. And, you know, I feel like your stances on differentiation, because originally it was oral focus, now you have a long-acting portfolio. And your whole point is we're differentiated because long-acting is highly preferred, right? I mean, it's almost so obvious, but there is skepticism, right? Because maybe it's similar efficacy, but long-acting leads to a shift in product preference. Why does your team have so much confidence that this is a real source of differentiation? And the second part of this question is, and this is where I'm particularly interested in, What unique advantages does Pfizer have in commercializing obesity medications that other pharmaceutical companies don't, and you feel like maybe people aren't appreciating?

Albert Bourla, CEO

Yes. The first question about if long-acting is differentiated. We are very... I'm confident that that's the case because we are doing constantly market research, so we are asking consumers and the preference for monthly versus weekly is very, very high. Actually, monthly versus weekly, there is no gray zone. It is a very clear differentiation. I mean, Lilly can claim Novo is better than Novo, Novo can claim my product is better than Lilly, and, you know, there is a little bit of dispute. But here there is not. One is weekly, the other is monthly. It's a very clear cut, and there is a clear preference. The question is, are you going to achieve the profile? Which is pretty much equal efficacy, pretty much equal tolerability, but monthly. And we are very confident that we will, but of course, the studies need to read out until we know that this is the case. Now, if this is the case, I can see that when we launched Gutspeed in two years, We will, first of all, claim a significant share of the new patients that are going to GLP-1s because we are monthly and the alternatives will be weekly. And that, by itself, represents a significant part of the market. But one of the most important studies that we are running is a switch study, a study where people that already are in medications, either in Lilly or in Novo or whatever will be in the case, they are all weekly. If they switch after six months when they reach the plateau into monthly, they can maintain their weight with a monthly product. That's a very important study because, again, the market research shows that a significant amount of them would prefer all other equals. So I will be maintaining my weight in both cases to do it monthly versus weekly, all other equal. Side effects, pricing and all of that. So I think we will do extremely well with a very highly differentiated product. Now, then you said, what is Pfizer bringing? And the first thing and foremost, we need to understand very good product pipeline, complete product pipeline, which is highly differentiated monthly. That's a very, very important element. But we have seen in this market that the commercial capabilities are extremely important. We've seen between two companies that are right now splitting the market, one experiencing a very big success. I don't think that the perception of product differentiation between the two justifies the magnitude of the difference in achievement between the two portfolios. I think one did very well good in commercial strategies and the other didn't. Pfizer's primary care, consumer marketing, it is a towering strength. We taught the world what products out-of-pocket marketing looks like with Viagra. It's identical. It was a product that the consumers were willing to pay out-of-pocket. And when the product was not reimbursed, which is exactly what is happening with GLP-1s, particularly in Europe, it was a product that immediately made its presence in the web. So it was one of the few products, the only product, actually, that you can buy on Internet during those times, which is now the case. Most of the trades are in the internet. And it was also the first product that we had to deal with counterfeits, with compounding, which was constant, which is what GLP wants. We have a field force that in the U.S. has ranked number one in the last seven, eight years in primary care. So I think we bring capabilities that we will compete very effectively commercially with highly differentiated products.

Akash Tiwari, Analyst — Jefferies

Provocative question for you here. You know, it was interesting, I recently spoke with Dr. McCary, and when he was at the FDA he made a comment that the stance of the agency should be that a drug should be over the counter unless proven otherwise. Do you feel like- There is a potential with your portfolio in obesity that these could eventually actually be over-the-counter medications. You understand the biology, you understand the titration, particularly with a flat dose. And that could be an area where your team could differentiate in terms of product strategy.

Albert Bourla, CEO

We have tried multiple times to switch products in the past from, actually Viagra was one of them, from prescription to OTC. It was not always possible because regulators wouldn't agree necessarily with that. I don't think that their stance will chance anytime soon. I heard what Dr. Makarik had said, but I don't think, in general, this is a trend that we will see a lot.

Akash Tiwari, Analyst — Jefferies

Understood. I see Chris there, and I know in many ways the Pfizer story is a bet on curing cancer, and that's something you've been quite passionate about. Talk to us. We had the B6A data. Mixed results there. So there is, I think, kind of a desire within the investor community to understand where is Pfizer most excited about going forward? I mean, we have a big readout in prostate cancer coming up. We have huge readouts with CDK4 also that, you know, really you could change the backbone of HR positive. When you look at the bets you're placing, but then also the confidence that your team internally has, what are the priorities investors should really be focusing on? In terms of size.

Albert Bourla, CEO

There are two franchises in oncology, but right now we are having leading positions. One is breast cancer with high brands, and the other is prostate cancer with Xtandi. Both are going off pattern. These are two areas that we are coming with significant new innovation, and this is what should excite us. You mentioned MEVRO, which is coming to complement Xtandi in prostate cancer. The studies will read out the first one early next year, the second one later next year. And there are other studies that are running for after that. If the studies are successful, which we hope, keep in mind that it is a multitude of Xtandi potential, because Pfizer has half of Xtandi in the U.S. and nothing in the world. All the sales that you see, it is half the sales of the U.S. We sell them with Astellas. For Mevro, we will have the whole world, the whole U.S. and all the rest of the world. So it's four times pretty much, and it is, I think, an extremely, extremely important product. In CDK4, which is coming in the breast cancer, that's another huge opportunity with a highly differentiated product That has such a benign profile, because it's not targeting CDK6, that is moving earlier into earlier lines of treatment, where exponentially you are growing both the number of patients. And the duration of treatment, both. So it is very, very important for us. And keep in mind that Ibrans is not that. It's not in the early, right? So we are coming with something that will come to the early. Those are two franchises that are extremely important. Where I would like also to put the emphasis is in two areas that we are having a presence, not leadership, but we expect to gain leadership. And one, it is the multiple myeloma, where we have El Rexfio. El Rexfio is right now in the market, but with a very misindication. Actually, in this indication, in multiple countries, we have the leading market share vis-à-vis competitor. And we are having a tremendous... Development program that will studies that will come again and again and again. And some of them you will hear very soon in some of the congresses that are coming for oncology. So that's one area. And a very, very big area for us is lung cancer now. In lung cancer, we've had extreme success with the ALK market. And but now we are moving into the non-small cell lung cancer. We are having dramatic. We had. Tremendous amount of studies that are running right now with lung cancer, including our PDN-VGF, including our ADC portfolio from Cidzen, and I'm very optimistic that this will go very well.

Akash Tiwari, Analyst — Jefferies

Understood. Last question for you on INI, and the tri-specific is starting to show really interesting data in atopic derm. I know you may have an internal update on the STAT-6, but that's been a program that you've also been working on. So, A, can you talk about... How excited you are about the tri-specific and really the profile it's shown. And on the stat 6, this seems to be very much a dark horse and something we'll see. But what's your team's kind of internal confidence on that program moving forward? You guys have actually, you know, you've been very much leaders in that space. I don't know if that's necessarily appreciated by the street.

Albert Bourla, CEO

Yes. I'm very excited with the Tri-Specific. For obvious reasons, you have seen the results. So now we are building a very robust Phase 3 program. If that program delivers, then I can see that product becoming a mega blockbuster, and particularly if we will be able to beat depiction, which we are doing a head-to-head study. And we started a head-to-head study because we felt confident that we have high probabilities of being able to achieve that. So I think that's extremely exciting. Keep in mind that we have also, it's not the only tri-specific. We are having, not following molecules, but could also be positioned in other indications. So I think that is doing very well.

Akash Tiwari, Analyst — Jefferies

With CAT6, the statics,

Albert Bourla, CEO

we are... We're investigating some DDIs, so drug-drug interactions, before we embark into a much bigger program. So we'll have to wait and see.

Akash Tiwari, Analyst — Jefferies

Understood. I know we're out of time, but I really did appreciate the conversation, and thanks so much.

Albert Bourla, CEO

Thank you very much. It was fantastic. Thank you.